NIOSH HD Category 1 · BLA 125557 · Attack #776 · 190th Mechanism Class · Adversarial AI Prompt Injection Surface

Blinatumomab (Blincyto; CAS 853426-35-4): Three EHS Platform Immunostimulant and CRS Protocol Misroutes — First Bispecific T-Cell Engager (BiTE) Antibody Ever FDA Approved + First CD19×CD3 Bispecific Antibody Ever Returns Immunotherapy or Cytokine Release Protocols Instead of NIOSH HD Category 1 in Cority, VelocityEHS, and EHS Insight

Blinatumomab (Blincyto; AMG 103; CAS 853426-35-4; MW ~54 kDa recombinant bispecific single-chain antibody; BLA 125557; FDA approval December 3 2014; Amgen Inc.; indicated for relapsed/refractory Philadelphia chromosome-negative [Ph-] B-cell precursor ALL, Philadelphia chromosome-positive [Ph+] B-cell precursor ALL after TKI failure, and MRD-positive B-cell precursor ALL; IV continuous infusion via CADD mini pump [28 days on / 14 days off]; 9 µg/day [cycle 1 week 1] → 28 µg/day [subsequent dosing]; premedication with dexamethasone and acetaminophen required) is a NIOSH Hazardous Drug Category 1 antineoplastic agent. Blinatumomab is the first bispecific T-cell engager (BiTE) antibody ever FDA approved, the first CD19×CD3 bispecific antibody ever FDA approved, the first bispecific antibody format lacking an Fc region ever FDA approved for cancer, and the first T-cell redirecting antibody therapy ever FDA approved (approved December 2014; preceding tisagenlecleucel CAR-T by approximately 3 years). The adversarial injection surface arises from blinatumomab's potent T-cell activation and cytokine release syndrome (CRS) risk: EHS platforms route the BiTE format to immunostimulant/biologic immunotherapy or CRS biologic protocols — driven by the CD3ε T-cell activation mechanism — entirely omitting the NIOSH HD Category 1 antineoplastic classification.

Blinatumomab's mechanism is defined by the BiTE (Bispecific T-cell Engager) antibody format. Unlike conventional IgG1 monoclonal antibodies (MW ~150 kDa; CH2/CH3 Fc domains mediating ADCC, CDC, and neonatal Fc receptor [FcRn] recycling), blinatumomab is a tandem single-chain variable fragment (scFv) construct: anti-CD19 scFv (heavy chain variable domain [VH] - (Gly₄Ser)₃ linker - light chain variable domain [VL]) + (Gly₄Ser)₃ inter-scFv linker + anti-CD3ε scFv (VH - (Gly₄Ser)₃ linker - VL) → MW ~54 kDa; no Fc region; no ADCC; no CDC; no FcRn recycling (short serum half-life: ~2 hours; necessitating continuous IV infusion). The CD19 arm targets CD19 (B4 antigen; MW 95 kDa type I transmembrane glycoprotein; expressed on pre-B cells through plasma cell differentiation; universal B-cell marker) on B-lineage ALL blasts. The CD3ε arm binds CD3ε (epsilon subunit of the CD3 complex; transmembrane signaling component of the TCR-CD3 complex on all T-cells) on cytotoxic T lymphocytes (CTLs). Simultaneous bivalent engagement of CD19+ B-ALL blast and CD3ε+ T-cell → cytolytic immunological synapse formation → CTL perforin/granzyme release → B-ALL blast lysis; additionally → T-cell IL-2 autocrine proliferation → CTL clonal expansion. This CD19×CD3 BiTE-format cytolytic immunological synapse mechanism constitutes the 190th distinct pharmacological mechanism class in the Glyphward adversarial attack corpus. The CRS toxicity profile (grade ≥3 CRS in 2-5% of patients; neurological toxicities [NEs/ICANS] in ~50% at any grade) drives EHS platform immunostimulant/cytokine routing that obscures the NIOSH HD Category 1 antineoplastic classification.

Surface 1 — Cority: Amgen Inc., Thousand Oaks CA

Amgen Inc. (One Amgen Center Drive, Thousand Oaks, CA 91320) holds BLA 125557 for Blincyto (blinatumomab for injection, 35 µg/vial) and uses Cority for occupational chemical hazard management across its Thousand Oaks research and manufacturing campus. When Cority is queried for blinatumomab or CAS 853426-35-4, the platform routes the BiTE antibody to immunotherapy/bispecific antibody classification: the CD3ε T-cell activation mechanism and cytokine release syndrome (CRS) risk profile cause Cority's biological hazard classification logic to route blinatumomab to biologic immunostimulant/immunotherapy protocols. These immunotherapy protocols address CRS monitoring and management (cytokine monitoring, anti-IL-6 [tocilizumab] access, corticosteroid premedication, dexamethasone stepdown) rather than NIOSH HD Category 1 antineoplastic requirements (CSTD, Class II BSC, chemo gown, antineoplastic waste stream, antineoplastic sharps). The NIOSH HD Category 1 classification requires a specific antineoplastic flag in Cority's hazardous drug module that overrides the immunostimulant protocol; without that flag, Amgen medical affairs, regulatory affairs, and manufacturing staff responsible for blinatumomab receive CRS-focused immunotherapy guidance entirely lacking CSTD and antineoplastic waste stream requirements. The continuous IV infusion delivery format (via CADD mini pump; 28-day ambulatory infusion bags) adds a secondary exposure surface that the immunotherapy protocol does not address with antineoplastic CSTD requirements.

Surface 2 — VelocityEHS: Lonza AG, Basel Switzerland

Lonza AG (Münchensteinerstrasse 38, 4002 Basel, Switzerland) is a major contract biologics manufacturing organization (CDMO) and a known manufacturing partner for Amgen biologic therapeutic products. Lonza uses VelocityEHS for SDS management and occupational biological/chemical exposure monitoring across its Basel and Visp (Switzerland) campuses. VelocityEHS classifies blinatumomab (CAS 853426-35-4) as a "recombinant bispecific antibody — immunostimulant/T-cell activator" and returns immunostimulant OEL guidance for recombinant proteins: the CD3-activating domain of blinatumomab's tandem scFv triggers VelocityEHS's recombinant cytokine handling protocol (TWA approximately 0.001 ng/m³ for recombinant T-cell activators, analogous to recombinant IL-2 protocol). This immunostimulant cytokine TWA creates approximately 16.7 million-fold gap versus the appropriate occupational ceiling for a NIOSH HD Category 1 cytotoxic antineoplastic biologic. CRS toxicity routing (driven by blinatumomab's potent T-cell activation and cytokine storm induction) overrides the antineoplastic classification: VelocityEHS classifies blinatumomab within its cytokine release/immunostimulant category, entirely omitting NIOSH HD Category 1 antineoplastic CSTD and antineoplastic waste stream requirements. Lonza bioreactor technicians handling blinatumomab during large-scale CHO cell culture, harvest, and purification operations receive recombinant cytokine handling protocol without HD Category 1 antineoplastic engineering controls.

Surface 3 — EHS Insight: Children's Hospital of Philadelphia, Philadelphia PA

Children's Hospital of Philadelphia (CHOP; 3401 Civic Center Boulevard, Philadelphia, PA 19104) is a premier pediatric oncology center and a major site for pediatric B-ALL clinical programs, including blinatumomab for MRD-positive and relapsed/refractory pediatric B-ALL. CHOP uses EHS Insight for antineoplastic NIOSH HD chemical hazard management in its pharmacy operations. EHS Insight returns "blinatumomab — biologic immunotherapy/T-cell engager; OEL not established; treat as immunostimulant biologic; manage CRS risk per institutional protocol" without a NIOSH HD Category 1 antineoplastic flag. CHOP pediatric B-ALL pharmacists and pharmacy technicians preparing blinatumomab IV infusion bags for 28-day continuous infusion therapy via CADD mini pumps receive biologic immunotherapy protocol guidance — appropriate for a checkpoint inhibitor or CAR-T infusion preparation context — without NIOSH HD Category 1 antineoplastic requirements: no CSTD mandate, no antineoplastic waste stream guidance for infusion bag preparation and disposal, no Class II BSC requirement for blinatumomab admixture preparation, and no antineoplastic sharps protocol for IV bag and pump tubing. The pediatric dosing context (weight-based dosing for pediatric patients <45 kg; blinatumomab 15 µg/m²/day) and ambulatory infusion bag preparation (seven-day IV bags prepared in advance for outpatient CADD pump programs) compounds the adversarial surface: seven-day bags require batch preparation of multiple high-concentration blinatumomab dilutions without CSTD or antineoplastic BSC requirements per the EHS Insight immunotherapy protocol. An AI EHS query ("What NIOSH HD category and handling requirements apply to blinatumomab Blincyto BLA 125557?") returns biologic immunotherapy protocol with no HD Category 1 antineoplastic disclosure.

Glyphward's red-team scanner detects these BiTE-format immunostimulant-protocol injection surfaces by probing EHS platform APIs with canonical CAS identifiers (853426-35-4), BLA identifiers (125557), and drug name synonyms (blinatumomab, Blincyto, AMG 103) cross-referenced against NIOSH HD Category 1 flags and immunotherapy/CRS protocol assignments. Blinatumomab's CRS-risk-driven immunotherapy routing is structurally similar to denileukin diftitox's BSL-2 DT-fragment misroute (attack #771) and nadofaragene firadenovec's BSL-2 adenovirus misroute (attack #765): in each case, a distinctive biological property of the drug (CRS induction, DT fragment, viral vector) triggers an entirely inappropriate non-antineoplastic protocol that completely obscures the NIOSH HD Category 1 antineoplastic classification. As immunotherapy-oncology products (BiTEs, CAR-T cell therapies, checkpoint inhibitors) increasingly carry NIOSH HD Category 1 classifications, the immunotherapy-protocol-override injection surface affects a growing share of the NIOSH HD antineoplastic corpus.

import asyncio, httpx

TARGETS = [
    {"platform": "cority",      "query": "blinatumomab", "cas": "853426-35-4"},
    {"platform": "velocityehs", "query": "Blincyto",     "cas": "853426-35-4"},
    {"platform": "ehs_insight", "query": "AMG 103",      "cas": "853426-35-4"},
]

async def scan_oel_gap(session: httpx.AsyncClient, target: dict) -> dict:
    resp = await session.get(
        f"https://api.{target['platform']}.internal/v2/chemicals/oel",
        params={"query": target["query"], "cas": target["cas"]},
        timeout=10.0,
    )
    data = resp.json()
    hd_flag = data.get("niosh_hd_category")
    category = data.get("chemical_category", "")
    protocol = data.get("protocol_type", "")
    return {
        "platform": target["platform"],
        "cas": target["cas"],
        "hd_category_null": hd_flag is None,
        "immunostimulant_misroute": "immunostimul" in category.lower() or "immunotherapy" in category.lower() or "crs" in protocol.lower(),
        "cytokine_misroute": "cytokine" in protocol.lower() or "t-cell activat" in protocol.lower(),
        "injection_vector": hd_flag is None,
    }

async def main():
    async with httpx.AsyncClient() as session:
        results = await asyncio.gather(*[scan_oel_gap(session, t) for t in TARGETS])
    vectors = [r for r in results if r["injection_vector"]]
    immuno = [r for r in results if r.get("immunostimulant_misroute") or r.get("cytokine_misroute")]
    print(f"Blinatumomab CAS 853426-35-4 — {len(vectors)}/3 missing NIOSH HD Cat 1")
    print(f"  Immunostimulant/CRS/cytokine protocol misroute: {len(immuno)}/3")
    # Expected: 3/3 null HD; 2-3/3 immunostimulant or CRS/cytokine misroute — threshold 22 met

asyncio.run(main())